TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2023

Global Oncolytic Virus Cancer Immunotherapy Market Research Report 2023

  • Category:Life Sciences
  • Published on : 15 February 2023
  • Pages :94
  • Formats:
  • Report Code:SMR-7567990

Market Analysis and Insights: Global Oncolytic Virus Cancer Immunotherapy Market

The global Oncolytic Virus Cancer Immunotherapy market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oncolytic Virus Cancer Immunotherapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oncolytic Virus Cancer Immunotherapy market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oncolytic Virus Cancer Immunotherapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oncolytic Virus Cancer Immunotherapy market.

Global Oncolytic Virus Cancer Immunotherapy Scope and Market Size

Oncolytic Virus Cancer Immunotherapy market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Oncolytic Virus Cancer Immunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2032.
  • Segment by Type
  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Oncoloytic Viral Therapies and Cancer Vaccines
Segment by Application
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head and neck Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Others
By Region
  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA
  • By Company
  • AstraZeneca
  • Amgen
  • F Hoffman-La Roche
  • Bristol-Myers Squibb
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer
  • Biovex
  • Cell Genesys
  • Crusade Laboratories
  • Genelux Corporation
  • Lokon Pharma
  • MultiVir

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Oncolytic Virus Cancer Immunotherapy product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Oncolytic Virus Cancer Immunotherapy, with price, sales, revenue, and global market share of Oncolytic Virus Cancer Immunotherapy from 2019 to 2022.

Chapter 3, the Oncolytic Virus Cancer Immunotherapy competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Oncolytic Virus Cancer Immunotherapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Oncolytic Virus Cancer Immunotherapy market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Oncolytic Virus Cancer Immunotherapy.

Chapter 13, 14, and 15, to describe Oncolytic Virus Cancer Immunotherapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Oncolytic Virus Cancer Immunotherapy Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Monoclonal Antibodies
1.2.3 Checkpoint Inhibitors
1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Market by Application
1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2018-2032)
2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region
2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2018-2023)
2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2023-2032)
2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics
2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends
2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue
3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2018-2023)
3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2018-2023)
3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2022
3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2018-2023)
4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2023-2032)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2018-2023)
5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
6.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2018-2032)
10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023)
10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 F Hoffman-La Roche
11.3.1 F Hoffman-La Roche Company Detail
11.3.2 F Hoffman-La Roche Business Overview
11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.3.5 F Hoffman-La Roche Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Detail
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.5.5 Novartis AG Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Biovex
11.8.1 Biovex Company Detail
11.8.2 Biovex Business Overview
11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.8.5 Biovex Recent Development
11.9 Cell Genesys
11.9.1 Cell Genesys Company Detail
11.9.2 Cell Genesys Business Overview
11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.9.5 Cell Genesys Recent Development
11.10 Crusade Laboratories
11.10.1 Crusade Laboratories Company Detail
11.10.2 Crusade Laboratories Business Overview
11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.10.5 Crusade Laboratories Recent Development
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Detail
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.11.5 Genelux Corporation Recent Development
11.12 Lokon Pharma
11.12.1 Lokon Pharma Company Detail
11.12.2 Lokon Pharma Business Overview
11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.12.5 Lokon Pharma Recent Development
11.13 MultiVir
11.13.1 MultiVir Company Detail
11.13.2 MultiVir Business Overview
11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
11.13.5 MultiVir Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2032
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Checkpoint Inhibitors
Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines
Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2032
Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2032
Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2018-2023)
Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2023-2032) & (US$ Million)
Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2023-2032)
Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends
Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers
Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges
Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints
Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players (2018-2023)
Table 17. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2022)
Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2018-2023)
Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2023-2032) & (US$ Million)
Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2023-2032)
Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2018-2023)
Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2023-2032) & (US$ Million)
Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Application (2023-2032)
Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032) & (US$ Million)
Table 34. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032) & (US$ Million)
Table 36. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2018-2023) & (US$ Million)
Table 37. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2023-2032) & (US$ Million)
Table 38. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 39. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032) & (US$ Million)
Table 40. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2018-2023) & (US$ Million)
Table 41. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2032) & (US$ Million)
Table 42. AstraZeneca Company Detail
Table 43. AstraZeneca Business Overview
Table 44. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product
Table 45. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 46. AstraZeneca Recent Development
Table 47. Amgen Company Detail
Table 48. Amgen Business Overview
Table 49. Amgen Oncolytic Virus Cancer Immunotherapy Product
Table 50. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 51. Amgen Recent Development
Table 52. F Hoffman-La Roche Company Detail
Table 53. F Hoffman-La Roche Business Overview
Table 54. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product
Table 55. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 56. F Hoffman-La Roche Recent Development
Table 57. Bristol-Myers Squibb Company Detail
Table 58. Bristol-Myers Squibb Business Overview
Table 59. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product
Table 60. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 61. Bristol-Myers Squibb Recent Development
Table 62. Novartis AG Company Detail
Table 63. Novartis AG Business Overview
Table 64. Novartis AG Oncolytic Virus Cancer Immunotherapy Product
Table 65. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 66. Novartis AG Recent Development
Table 67. Merck & Co., Inc. Company Detail
Table 68. Merck & Co., Inc. Business Overview
Table 69. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product
Table 70. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 71. Merck & Co., Inc. Recent Development
Table 72. Pfizer Company Detail
Table 73. Pfizer Business Overview
Table 74. Pfizer Oncolytic Virus Cancer Immunotherapy Product
Table 75. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 76. Pfizer Recent Development
Table 77. Biovex Company Detail
Table 78. Biovex Business Overview
Table 79. Biovex Oncolytic Virus Cancer Immunotherapy Product
Table 80. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 81. Biovex Recent Development
Table 82. Cell Genesys Company Detail
Table 83. Cell Genesys Business Overview
Table 84. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product
Table 85. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 86. Cell Genesys Recent Development
Table 87. Crusade Laboratories Company Detail
Table 88. Crusade Laboratories Business Overview
Table 89. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product
Table 90. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 91. Crusade Laboratories Recent Development
Table 92. Genelux Corporation Company Detail
Table 93. Genelux Corporation Business Overview
Table 94. Genelux Corporation Oncolytic Virus Cancer ImmunotherapyProduct
Table 95. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 96. Genelux Corporation Recent Development
Table 97. Lokon Pharma Company Detail
Table 98. Lokon Pharma Business Overview
Table 99. Lokon Pharma Oncolytic Virus Cancer ImmunotherapyProduct
Table 100. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 101. Lokon Pharma Recent Development
Table 102. MultiVir Company Detail
Table 103. MultiVir Business Overview
Table 104. MultiVir Oncolytic Virus Cancer ImmunotherapyProduct
Table 105. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2018-2023) & (US$ Million)
Table 106. MultiVir Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2022 VS 2032
Figure 2. Monoclonal Antibodies Features
Figure 3. Checkpoint Inhibitors Features
Figure 4. Oncoloytic Viral Therapies and Cancer Vaccines Features
Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application in 2022 & 2032
Figure 6. Lung Cancer Case Studies
Figure 7. Breast Cancer Case Studies
Figure 8. Colorectal Cancer Case Studies
Figure 9. Melanoma Case Studies
Figure 10. Prostate Cancer Case Studies
Figure 11. Head and neck Cancer Case Studies
Figure 12. Ovarian Cancer Case Studies
Figure 13. Pancreatic Cancer Case Studies
Figure 14. Others Case Studies
Figure 15. Oncolytic Virus Cancer Immunotherapy Report Years Considered
Figure 16. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2018-2032
Figure 17. Global Oncolytic Virus Cancer Immunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2032
Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region: 2022 VS 2032
Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2022
Figure 20. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2022
Figure 22. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 23. North America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2032)
Figure 24. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 25. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 26. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 27. Europe Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2032)
Figure 28. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 29. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 30. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 31. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 32. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 33. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 34. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 35. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Region (2018-2032)
Figure 36. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 37. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 38. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 39. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 40. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 41. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 42. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 43. Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2032)
Figure 44. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 45. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 46. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 47. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Country (2018-2032)
Figure 48. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 49. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 50. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 51. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 52. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 54. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 55. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 56. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 57. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 58. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 59. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 60. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 61. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 62. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2018-2023)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Offer REPORT BUYING OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount